Document is current
Any future updates will be listed below
-
Authors
LeSavage, Bauer L. https://orcid.org/0000-0002-4897-9436
Zhang, Daiyao https://orcid.org/0009-0005-7259-0948
Huerta-López, Carla
Gilchrist, Aidan E. https://orcid.org/0000-0003-3536-1044
Krajina, Brad A.
Karlsson, Kasper https://orcid.org/0000-0003-0162-1354
Smith, Amber R.
Karagyozova, Kremena
Klett, Katarina C.
Huang, Michelle S. https://orcid.org/0000-0002-1814-7786
Long, Christopher
Kaber, Gernot https://orcid.org/0000-0002-6184-5192
Madl, Christopher M. https://orcid.org/0000-0003-3221-5041
Bollyky, Paul L.
Curtis, Christina
Kuo, Calvin J.
Heilshorn, Sarah C. https://orcid.org/0000-0002-9801-6304
-
Funding
Funding for this research was provided by:
U.S. Department of Health Human Services | National Institutes of Health (R01 EB027171, DP1CA238296, U01CA217851, U01CA217851, U54CA224081)
National Science Foundation (CBET 2033302)
Stand Up to Cancer
- License Information
-
More Information
Article History
Received: 25 April 2022
Accepted: 30 April 2024
First Online: 4 July 2024
Competing interests
: S.C.H. has a patent application pending related to the hydrogel formulations used in this paper, as described in an international patent application PCT/US/2021/057925 with an international filing date of 3 November 2021. This application has been submitted to the U.S. Patent Office and published on 16 November 2023 as US 2023-0365940 A1, and this same application has entered the national phase in China (publication number 116829126), Singapore (application number 11202303493U), Europe (publication number 4240327), Japan (serial number 2023-526661), Canada (serial number 3,196,621), Israel (serial number 302453), South Korea (serial number 10-2023-7018686) and Australia (serial number 2021376143). The named inventors are S. Heilshorn, R. Suhar and D. Hunt, and the named applicant is the Board of Trustees of the Leland Stanford Junior University. C.C. is an advisor and holds equity in Grail, Ravel and Deepcell, and is an advisor to Genentech and NanoString. C.J.K. is an advisor and holds equity in Surrozen, Mozart and NextVivo. The other authors declare no competing interests.
